[Continuous enoximone infusion in patients with severe heart failure in dilated cardiomyopathy, hemodynamic, neurohumoral, chemical laboratory and clinical results].
The hemodynamic, clinical, and neurohumeral effects of a prolonged (6-days) intravenous enoximone-infusion therapy were evaluated in 12 patients suffering from severe cardiac failure due to dilated cardiomyopathy. The loading dose of enoximone was 1.5 mg/kg. The maintenance dose during the two phases of constant intravenous infusion were 4 and 8 mcg/kg/min, respectively. The enoximone infusion therapy produced sustained salutary effects on cardiac hemodynamics and on clinical status in every patient. The enoximone infusion therapy caused a decrease in mean pulmonary artery pressure by 38%, an increase in cardiac index by 60%, the pulmonary and systemic vascular resistance decreased by 61% and 37%, respectively. Side effects and therapy-related cardiac arrhythmias were not observed.


CONCLUSIONS
Enoximone infusion therapy provides sustained salutary hemodynamic and clinical effects in patients with severe cardiac failure.
Neuzner
J
J
Kerckhoff-Klinik, Bad Naurheim.
Mitrovic
V
V
Pitschner
H F
HF
Lissmann
H
H
Schlepper
M
M
D000450:Aldosterone / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood; D002311:Cardiomyopathy, Dilated / Q000097:blood / Q000188:drug therapy*; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D017335:Enoximone / Q000031:analogs & derivatives; D004837:Epinephrine / Q000097:blood; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007262:Infusions, Intravenous; D018377:Neurotransmitter Agents / Q000097:blood*; D009638:Norepinephrine / Q000097:blood; D012083:Renin / Q000097:blood
D002316:Cardiotonic Agents; D007093:Imidazoles; D018377:Neurotransmitter Agents; D000450:Aldosterone; C041258:enoximone sulfoxide; D009320:Atrial Natriuretic Factor; D017335:Enoximone; D012083:Renin; D009638:Norepinephrine; D004837:Epinephrine
Enoximon-Dauerinfusion bei Patienten mit schwerster Herzinsuffizienz bei dilatativer Kardiomyopathie, Hämodynamische, neurohumerale, laborchemische und klinische Ergebnisse.